Federated Hermes Inc. Reduces Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Federated Hermes Inc. trimmed its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 96.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,606 shares of the specialty pharmaceutical company's stock after selling 40,453 shares during the period. Federated Hermes Inc.'s holdings in Supernus Pharmaceuticals were worth $58,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after acquiring an additional 22,852 shares during the period. Geode Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after purchasing an additional 28,517 shares during the period. American Century Companies Inc. raised its position in shares of Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after purchasing an additional 95,777 shares during the period. Charles Schwab Investment Management Inc. increased its position in Supernus Pharmaceuticals by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after acquiring an additional 40,968 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Supernus Pharmaceuticals by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock valued at $14,449,000 after purchasing an additional 27,134 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,104 shares of company stock valued at $440,263. Corporate insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN traded up $0.29 during trading hours on Thursday, hitting $31.13. The company had a trading volume of 47,728 shares, compared to its average volume of 566,294. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The firm has a 50 day simple moving average of $32.25 and a 200 day simple moving average of $34.98. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of 29.14 and a beta of 0.90.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.